Home » News: Global Pharmaceutical Contract Manufacturing Market to Reach US$40.7 Billion by 2015
News: Global Pharmaceutical Contract Manufacturing Market to Reach US$40.7 Billion by 2015
The global market for pharmaceutical contract manufacturing witnessed robust growth in recent years, and the future continues to hold tremendous prospects for the industry. With the onset of global economic recession, several countries in the developed world began scouting for ways to minimize expenditure on drugs. Resultantly, pharmaceutical companies were compelled to seek ways of minimizing cost of drugs, which in turn forced them to evaluate opportunities for manufacturing outsourcing.
Despite tough times faced by companies in the pharmaceutical contract manufacturing industry during the recession, overall market maintained a positive growth posting only a moderate slowdown in growth. However, a drop in venture capital funding due to the recession has compelled many pharmaceutical and biotechnology companies to cut down on spending, affecting the fortunes of contract manufacturers worldwide. As a result, several projects were kept on hold and new project starts were delayed, cascading the impact of the pharmaceutical industry to the outsourcing industry as well.
Global pharma industry has been witnessing drastic changes such as increasing competition in generic markets, declining research and development (R&D) productivity, shrinking average patent life, and mounting governmental pressure to reduce drug prices. Further, the drug development process is known to extend over a period ranging from 8 to 15 years, and the cost of bringing out a single new molecule into the market is more than US$800 million. With limited new blockbuster drugs, the decisive factors for growth and sustainability are faster new drug development and cost containment. When the drug gets regulatory approval, pharma companies will require large quantities of product supplies for marketing and distribution. Given the considerable timelines of drug development, it is not only difficult to project a company's manufacturing needs but also challenging to procure extensive capital requirements. As a result, PCM outsourcing emerged to bail out pharma companies from these manufacturing uncertainties. Initially, it gained popularity in the US and Western Europe. Over the years, PCM outsourcing shifted its base to low-cost nations.
Today, manufacturing capacity constraints are only one of the reasons for outsourcing. Pharmaceutical manufacturing entails sophisticated technology (cGMP synthesis and scale up, impurity profiling, lyophilization) and strict regulatory compliance (good manufacturing practices - GMP). Outsourcing such activities to Contract Manufacturing Organizations (CMOs) enables a pharma company to expedite its R&D, and thus realize the potential revenues. Moreover, CMOs are increasingly offering a wide range of value-added services, which make PCMO an indispensable opportunity to pharma companies.
The US represents the largest regional market for Pharmaceutical Contract Manufacturing worldwide, as stated by the new market research report on Pharmaceutical Contract Manufacturing. Europe trails behind the US. However, future growth in the market is expected to emanate from developing regions, such as Asia-Pacific. Japanese market for Pharmaceutical Contract Manufacturing alone is projected to register a compounded annual growth rate of 12.8% during the analysis period. Segment-wise, solid dosage forms represents the largest segment. The market for liquid dosage forms is projected to record a compounded annual growth rate of close to 6.0% during the analysis period.
Major players profiled in the report include Althea Technologies, Catalent Pharma Solutions, Dishman Pharmaceuticals and Chemicals Ltd, HAUPT Pharma AG, Jubilant Life Sciences Limited, Kemwell Pvt. Ltd, NextPharma, Nipro Corp., Patheon Inc., Royal DSM N.V., among others.
The research report titled "Pharmaceutical Contract Manufacturing: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the pharmaceutical contract manufacturing markets, impact of the recession on the market, current market trends, key growth drivers, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for pharmaceutical contract manufacturing market for the years 2007 through 2015 for the following geographic markets - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Key product segments analyzed include Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups & Suspensions). Also, a seven-year (2000-2006) historic analysis is provided for additional perspective.
For more details about this comprehensive market research report, please visit - www.strategyr.com/Pharmaceutical_Contract_Manufacturing_Market_Report.asp
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
Rapid Micro Biosystems Offers Workshops at New European Headquarters in MunichFrom Rapid Micro Biosystems
Company hosts hands-on demonstrations of its Growth Direct System
- All news »